Amarin Corp Plc (AMRN)

[James364202]

NEJM articles and JELIS are both suggestive of R-It success. I always appreciated SRs comments, this is what he had to say re NEJM articles. " extremely good for AMRN and AMRN longs. Even if FDA is not pressured to negotiate or grant appeal, bodes well for R-It study" and " Essentially, longs now have a backup plan B with some mitigated R-It risk. The new study(NEJM) strongly suggests JELIS wasn't BS."
I agree with his points, triglycerides and their reduction may be causitive of or marker for reduced CVE.